肠脑神经调节剂与脑肠行为疗法对肠易激综合征的疗效:系统综述与网络荟萃分析
该网络荟萃分析检索至2026年2月8日的随机对照试验,比较肠脑神经调节剂与脑肠行为疗法对成人肠易激综合征的疗效。共纳入68项RCT(6694例参与者),以全局IBS症状或腹痛未改善的二分类终点评估疗效。与等待列表对照相比,SNRIs排名第一(RR=0.49, 95%CI 0.32-0.75, P-score 0.95),TCAs第二(RR=0.60, 95%CI 0.43-0.85),动态心理治疗/情绪加工第三(RR=0.62, 95%CI 0.44-0.87),CBT、疾病自我管理、SSRIs和肠道导向催眠疗法也优于对照。
要点
- SNRIs在改善全局IBS症状或腹痛方面排名第一(RR=0.49, P-score 0.95),但无低偏倚风险试验。
- TCAs排名第二(RR=0.60, 95%CI 0.43-0.85),动态心理治疗/情绪加工排名第三(RR=0.62)。
- CBT、疾病自我管理、SSRIs和肠道导向催眠疗法也优于等待列表对照。
核心结论
- 多种肠脑神经调节剂(尤其是TCAs)和脑肠行为疗法(特别是动态心理治疗/情绪加工、CBT、疾病自我管理和GDH)对IBS有效。
- 部分分析可能存在发表偏倚,大多数比较的证据确定性为低或极低。
研究设计与样本
- 网络荟萃分析,检索医学文献至2026年2月8日,纳入肠脑神经调节剂或脑肠行为疗法治疗成人IBS的随机对照试验。
- 共纳入68项 eligible RCTs(6694例参与者)。
- 主要分析采用全局IBS症状或腹痛改善的二分类终点,使用随机效应模型合并数据,疗效以合并相对风险(RR)及95%CI报告。
- 采用P-score排名治疗,P-score表示一种治疗优于所有竞争治疗的平均确定性程度。
主要发现
- 与等待列表对照相比,66项试验(6542例患者)中,SNRIs在6项试验(387例患者)中排名第一(全局IBS症状或腹痛未改善的RR=0.49; 95%CI 0.32-0.75, P-score 0.95),即该治疗为最有效治疗的概率为95%。
- TCAs在15项试验(1519例患者)中排名第二(RR=0.60; 95%CI 0.43-0.85, P-score 0.79)。
- 动态心理治疗/情绪加工形式排名第三(RR=0.62; 95%CI 0.44-0.87, P-score 0.75)。
- CBT形式、疾病自我管理形式、SSRIs和肠道导向催眠疗法(GDH)形式也优于等待列表对照。
- 然而,没有试验处于低偏倚风险。
关键数值与推荐
- SNRIs:6项试验(387例患者),RR=0.49(95%CI 0.32-0.75),P-score 0.95。
- TCAs:15项试验(1519例患者),RR=0.60(95%CI 0.43-0.85),P-score 0.79。
- 动态心理治疗/情绪加工:RR=0.62(95%CI 0.44-0.87),P-score 0.75。
- CBT、疾病自我管理、SSRIs和GDH也优于等待列表对照(未报告具体数值)。
临床怎么用
- 对于IBS患者,可考虑使用肠脑神经调节剂如TCAs或SNRIs,以及脑肠行为疗法如动态心理治疗、CBT、疾病自我管理和肠道导向催眠疗法。
- 临床决策时应考虑证据确定性低至极低,且可能存在发表偏倚。
- 需结合患者具体情况和偏好选择治疗,并注意无低偏倚风险试验的限制。
局限性
- 部分分析可能存在发表偏倚。
- 大多数比较的证据确定性为低或极低。
- 没有试验处于低偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction, with some recommended treatments targeting brain-gut axis dysfunction. OBJECTIVE: To compare relative efficacy of gut-brain neuromodulators and brain-gut behaviour therapies in IBS. DESIGN: Network meta-analysis searching the medical literature to 8 February 2026 for randomised controlled trials (RCTs) of gut-brain neuromodulators or brain-gut behaviour therapies in adults with IBS. In our main analysis, we judged efficacy using dichotomous endpoints of improvement in either global IBS symptoms or abdominal pain. We pooled data with a random effects model, with efficacy reported as a pooled relative risk (RR) with 95% CIs. We ranked treatments according to P-score; the mean extent of certainty that one treatment is better than another averaged over all competing treatments. RESULTS: We identified 68 eligible RCTs (6694 participants). Compared with waiting list control, in 66 trials (6542 patients), serotonin and norepinephrine reuptake inhibitors (SNRIs) ranked first in six trials (387 patients) (RR of global IBS symptoms or abdominal pain not improving=0.49; 95% CI 0.32 to 0.75, P-score 0.95), meaning the probability that this was the most efficacious treatment was 95%. However, no trials were at low risk of bias. Tricyclic antidepressants (TCAs) ranked second in 15 trials (1519 patients) (RR=0.60; 95% CI 0.43 to 0.85, P-score 0.79) and forms of dynamic psychotherapy/emotional processing third (RR=0.62; 95% CI 0.44 to 0.87, P-score 0.75). Forms of cognitive behavioural therapy (CBT), forms of disease self-management, selective serotonin reuptake inhibitors and forms of gut-directed hypnotherapy (GDH) were also superior to waiting list control. CONCLUSION: Several gut-brain neuromodulators, especially TCAs, and brain-gut behaviour therapies, particularly forms of dynamic psychotherapy/emotional processing, CBT, disease self-management and GDH, are efficacious for IBS. However, there was possible publication bias in some analyses, and overall certainty in the evidence was low or very low for most comparisons.
引用
- Khasawneh M, Thakur ER, Goodoory VC, et al. Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2026. PMID: 42362221. doi:10.1136/gutjnl-2026-339311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。